Group 1 - The core reason for the strengthening of the US dollar since March is the relatively smaller impact on the US economy amid the Middle East conflict, leading to a return of funds to dollar assets, but this is not indicative of a liquidity crisis [1] - The narrative of a "weak dollar" has ended, reversing the previous trend of funds flowing from dollar assets to physical and other financial assets due to the US-Iran conflict [1] - Recent trends indicate that the strength of the US dollar may be nearing its end, with a potential confirmation of price bottoms for physical and non-US assets [1] Group 2 - Since late February, the vitamin market in Europe and domestically has experienced significant price volatility due to escalating Middle East conflicts and energy cost pressures, with Vitamin A prices increasing by nearly 82% and Vitamin E by over 75% [2] - The pharmaceutical team at Zhongyou Securities notes that the market space for related products may see effective recovery due to the combination of reversed supply-demand dynamics and geopolitical catalysts [2] - The raw material drug sector is currently driven by a dual momentum of "fundamental turning point + price increase expectations," with limited new capital expenditure in the past three years and a significant recovery potential for specific products like sartans and statins [3]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The animal health raw material drug prices are expected to experience a cyclical rebound in 2026 due to a recovery in industry demand and stabilization of antibiotic supply chain prices [1] - The heparin raw material drug industry is currently at a cyclical low, with prices declining sharply in 2023, but expected to stabilize by 2025 [2][56] - The vitamin industry is entering a price increase cycle influenced by geopolitical tensions and rising oil prices, leading to significant price increases for vitamin A and E [3][58] Summary by Sections Raw Material Prices and Trends - The PPI index for China's chemical raw materials has been on a downward trend, while upstream raw material prices are showing an upward trend, which may accelerate the supply clearance in the raw material drug industry [11][18] - Antibiotic prices, including 6-APA and penicillin industrial salt, are showing signs of recovery after hitting bottom [25][29] - The average price of florfenicol has dropped from 400-700 RMB/kg to 150-200 RMB/kg, indicating a significant decline due to oversupply and weak downstream demand [46][49] Investment Recommendations - The report suggests focusing on companies that have undergone thorough supply clearance and have expectations for price increases, recommending stocks such as Guobang Pharmaceutical, Puluo Pharmaceutical, and Aorite [4][72] - Beneficiary stocks include Meinuo Pharmaceutical, Chuaning Biological, and Zhejiang Pharmaceutical, among others [4][72] Price Trends in Specific Segments - Heparin API prices are expected to stabilize in 2025 after a period of decline due to oversupply [56][57] - Iodine raw material prices have seen a recovery due to strong demand from other industries, following a period of significant price increases [2][56] - The vitamin A and E prices are experiencing rapid increases due to geopolitical tensions affecting oil prices and supply chain disruptions [3][58]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 1, 2026 [1] Core Insights - The supply-side variables in the pharmaceutical industry are increasing, leading to an expansion in price adjustments. The raw material drug industry is particularly sensitive to these changes, with the penicillin supply chain already experiencing price rebounds. For instance, the import price limit for 6-APA has been set at approximately 260 RMB/kg, prompting domestic companies to raise their prices [2] - The GLP-1 oral medication era is actively beginning, with Chinese companies continuing to explore international markets. Notably, Eli Lilly's sales of its GLP-1 drug reached 36.5 billion USD in 2025, and the oral version of semaglutide has been launched in the U.S. market, showing strong initial prescription numbers [3] - The small nucleic acid field is witnessing ongoing collaborations and authorizations, with significant mergers and acquisitions occurring in 2026. For example, China National Pharmaceutical Group is acquiring a domestic siRNA innovator for 1.2 billion RMB [4] - The retail pharmaceutical market showed positive trends in Q4 2025, with a retail scale of 58.8 billion RMB, although the annual growth rate remained slightly negative at -0.57% [5] - The report emphasizes the market value of oral autoimmune drugs, highlighting Takeda's new oral TYK2 inhibitor showing promising results in clinical trials for psoriasis [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index underperformed the CSI 300 index by 0.58 percentage points in the last week, ranking 25th among 31 sectors [19] - Over the past month, the pharmaceutical industry index fell by 2.67%, also underperforming the CSI 300 index by 2.77 percentage points, ranking 28th [22] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 37.20, which is below the five-year historical average of 30.78 [40] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of biological agents and oral medications, indicating a positive outlook for psoriasis treatment [42] 4. Important Industry Policies and News - Recent policies include the approval of 292 medical device products by the National Medical Products Administration, indicating regulatory support for the industry [44] - Significant news includes Eli Lilly's positive clinical trial results for its drug, which may enhance its market position [46]

Investment Chain - The prices of non-ferrous metals have risen significantly since February 2026, with copper, aluminum, zinc, lead, tin, nickel, gold, and silver all experiencing price increases. However, fixed asset investment growth has declined, with real estate development investment down by 17.20% year-on-year and manufacturing fixed asset investment growth at only 0.60% [10][11] - In February 2026, the average price of ordinary cement decreased, while the prices of steel and light soda ash also fell. The sales growth of large and light buses declined, but the sales growth of medium-sized buses increased [10][11] Consumption Chain - In January 2026, the year-on-year growth rate of automobile sales showed a slight recovery, increasing to -3.18%. However, the consumer confidence index fell to 89.50 in December 2025, and retail sales growth for home appliances decreased by 14.25% [11][12] - The total retail sales of consumer goods in December 2025 saw a nominal year-on-year growth rate drop to 0.90%, with a cumulative decline of 3.70% [11][12] - Tourism revenue in Beijing increased by 11.40% year-on-year in December 2024, while tourism revenue in Hainan decreased by 20.03% in March 2024 [11][12] Export Chain - In December 2025, exports to Japan and ASEAN countries increased, while exports to the US and EU saw a decline. The export growth rate for electronic products rose to 37.25%, while textile exports fell by 4.23% [12][13] - The cumulative year-on-year growth rate for exports of refined oil, coke, steel, and aluminum increased, while the export amounts for agricultural products, toys, furniture, and other categories decreased [12][13] - The OECD leading indicator for the US rose to 100.50 in January 2026, indicating potential economic improvement [12][13] Price Chain - In February 2026, pork prices decreased to 12.75 yuan per kilogram, while oil prices increased, with WTI rising to 65.63 USD per barrel [13][14] - The price of PVC rose to 4770 yuan per ton, while the price of MDI fell to 13950 yuan per ton [13][14] - The price of cotton increased, and the price of white sugar decreased during the same period [13][14]

Investment Chain - Non-ferrous metal prices have risen since February 2026, with fixed asset investment growth in December 2025 declining to -3.80%[1] - Real estate development investment in December 2025 saw a year-on-year decline of 17.20%[1] - Manufacturing fixed asset investment growth in December 2025 decreased to 0.60%[1] - Infrastructure investment growth in December 2025 fell to -1.48%[1] Consumption Chain - In December 2025, the nominal year-on-year growth rate of social consumption fell to 0.90%, with a cumulative decline of 3.70%[2] - The consumer confidence index in December 2025 dropped to 89.50[2] - In January 2026, automobile sales saw a year-on-year growth rate increase to -3.18%[2] - Home appliance retail sales in December 2025 experienced a year-on-year decline of 14.25%[2] Export Chain - In December 2025, exports to Japan and ASEAN saw a year-on-year growth increase, while exports to the US and EU declined[3] - The export growth rate for electronic products in December 2025 rose to 37.25%[3] - Textile export value in December 2025 decreased by 4.23% year-on-year[3] - Mechanical export value in December 2025 increased by 6.60% year-on-year[3] Price Chain - As of February 2026, the price of pork decreased to 12.75 yuan/kg[4] - WTI crude oil price increased to $65.63 per barrel on February 24, 2026[4] - PVC spot price rose to 4770 yuan/ton on February 24, 2026[4] - The average price of coal in Qinhuangdao increased in February 2026[4]

Core Insights - The article highlights the challenges faced by visually impaired individuals in accessing and using medications safely due to the lack of accessible packaging and labeling [2][3][4] Group 1: Current Situation - In 2020, approximately 8.9 million blind individuals were reported in China, with a broader estimate of 17.32 million people with visual impairments [3] - The revised Drug Administration Law requires pharmaceutical companies to provide accessible formats for drug labels, including braille and large print, to assist disabled and elderly individuals [3] - Many visually impaired individuals rely on memory or tactile methods to identify medications, which can lead to dangerous mistakes, especially in emergencies [4][5] Group 2: Industry Response - Some pharmaceutical companies have begun to print braille on medication packaging, with examples including companies like Aojina Pharmaceutical and Beid Pharmaceutical [11][14] - The cost of adding braille to packaging is relatively low, increasing the cost by approximately 1-2 cents per box, but the adoption rate among companies remains low due to awareness and cost concerns [13][14] - There is a growing trend among younger visually impaired individuals to use AI tools for medication identification, with applications like Doubao AI providing real-time assistance [6][8] Group 3: Challenges and Limitations - Despite advancements, AI tools face limitations such as misidentification and reliance on internet connectivity, which can hinder their effectiveness in certain situations [9][10] - Many visually impaired individuals, particularly the elderly, may not be familiar with smartphones or AI applications, making traditional packaging improvements essential [10] - The use of braille is limited, with estimates suggesting that less than 10% of visually impaired individuals in certain regions can read it, highlighting the need for broader accessibility measures [16][19] Group 4: Future Directions - There is a call for more innovative packaging designs that enhance accessibility, such as using high-contrast colors and alternative shapes for medication containers [18][19] - Companies are exploring the integration of QR codes and voice-activated features to provide detailed medication information, which could improve safety for visually impaired users [17][19] - The industry is encouraged to raise awareness about the needs of visually impaired individuals to foster better design practices and improve medication safety [19]

Core Viewpoint - The report from Huachuang Securities indicates that while the industry is facing challenges due to increased competition, there is a stabilization and recovery in the prices of veterinary raw materials and vaccines, driven by innovation among successful companies [1] Vaccine Batch Release - In 2025, most vaccine varieties are expected to see year-on-year growth in batch releases, with new vaccines performing particularly well [1] - Specific growth rates for pig vaccines include: foot-and-mouth disease vaccine +6.4%, porcine circovirus vaccine +13.0%, pseudorabies vaccine +5.1%, swine fever vaccine +11.7%, and porcine enterovirus vaccine +21.3% [1] - For poultry vaccines, notable increases include avian influenza trivalent vaccine +22.8%, Newcastle disease vaccine +8.8%, and duck infectious serositis vaccine +17.3% [1] - The brucellosis vaccine for ruminants saw a significant increase of +61.6%, while the small ruminant plague vaccine decreased by -16.2% [1] - In the pet vaccine sector, domestic rabies vaccine and domestic cat trivalent vaccine increased by +22.1% and +32.3% respectively [1] Subspecies Analysis - In 2025, the economic product porcine circovirus vaccine and the mandatory immunization swine fever vaccine are expected to see faster growth due to increased farming profitability and pig output [2] - The rapid growth of the avian influenza trivalent vaccine and duck infectious serositis vaccine is attributed to heightened awareness of poultry diseases [2] - The brucellosis vaccine continues to maintain high growth rates due to the introduction of new products, while the small ruminant plague vaccine has seen a decline due to a high base from the previous year [2] Pet Vaccine Performance - The domestic cat trivalent vaccine, launched in early 2024, continues to show high growth in 2025 due to effective market promotion and consumer education [3] - Different types of vaccines for the same disease show varied performance, with the single foot-and-mouth disease vaccine decreasing by -0.7% and the multi-valent vaccine increasing by +8.9% [3] - The porcine foot-and-mouth disease OA bivalent vaccine saw a growth of +12.3%, while the porcine circovirus vaccine increased by +19.7% [3] Veterinary Raw Material Prices - In 2025, the Veterinary Product Index (VPI) is expected to rise by 7.2% year-on-year, with significant price increases in macrolide products [4] - Specific price increases include: tylosin +29.5%, tiamulin +11.4%, and tilmicosin +22.9% [4] - However, some products like florfenicol and amoxicillin have seen price declines of -5.9% and -21.0% respectively [4] - The market is anticipated to remain weak in the short term due to ongoing pressures in the farming sector and the traditional off-season for veterinary drugs [4]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 26, 2026 [1] Core Insights - The report emphasizes the importance of supply-side variables, particularly the operating rates of raw material drugs, and highlights the potential for price recovery in the antibiotic market due to changes in competition and supply dynamics [2] - Multi-departmental policy support is enhancing the value positioning of pharmacies, transforming them from mere sales points to comprehensive health service platforms [3] - The trend of Chinese innovative drugs going global is gaining momentum, with significant licensing deals and the need for continuous clinical data validation to support long-term investment confidence [4] - Major companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [5] - A new pricing system for GLP-1 drugs is forming in China, with significant market potential anticipated for weight loss and diabetes treatments [6] - The report highlights the market value of oral autoimmune drugs, with promising clinical trial results for new treatments [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.23 percentage points in the last week, ranking 27th among 31 sectors [20] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector index increased by 4.98% over the past month, outperforming the CSI 300 index by 3.21 percentage points [37] - The current PE (TTM) for the pharmaceutical sector is 38.51, above the five-year historical average of 31.06 [43] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of the blood products industry and the potential of GLP-1 drugs [45] 4. Recent Industry Policies and News - Recent policies include the promotion of high-quality development in the pharmaceutical retail sector and the approval of numerous medical devices by the National Medical Products Administration [46][48]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 26, 2026 [1] Core Insights - The report emphasizes the importance of supply-side variables, particularly the operating rates of raw material drugs, and highlights the potential for price recovery in the antibiotic market due to changes in competition and supply dynamics [2] - Multi-departmental policy support is enhancing the value positioning of pharmacies, transforming them from mere sales points to comprehensive health service platforms [3] - The trend of Chinese innovative drugs going global is gaining momentum, with significant licensing deals and the need for continuous clinical data validation to support long-term investment confidence [4] - Major companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [5] - A new pricing system for GLP-1 drugs is forming in China, with expectations for market growth driven by a large patient population [6] - The report highlights the market value of oral autoimmune drugs, with promising clinical trial results for new treatments [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.23 percentage points in the last week, ranking 27th among 31 sectors [20] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector index increased by 4.98% over the past month, outperforming the CSI 300 index by 3.21 percentage points [37] - The current PE (TTM) for the pharmaceutical sector is 38.51, above the five-year historical average of 31.06 [43] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of the blood products industry and the impact of policies on inhalation formulations [45] 4. Recent Industry Policies and News - Recent policies include the approval of numerous medical device registrations and the promotion of high-quality development in the pharmaceutical retail sector [46][48]

Core Viewpoint - The article highlights the challenges faced by small and medium-sized pharmacies in the current market, emphasizing the importance of digital tools for procurement and inventory management to enhance profitability and efficiency. Group 1: Challenges in the Pharmacy Industry - Many small pharmacy owners are struggling with rising costs such as rent and labor, leading to compressed profit margins [1] - The industry is experiencing a phenomenon known as "killing the familiar," where long-term relationships with suppliers may lead to overpaying due to a lack of price comparison [3] - On average, small pharmacies incur hidden losses of 50,000 to 80,000 yuan annually due to improper procurement practices [3] Group 2: Digital Tools and Their Benefits - Successful pharmacies are utilizing digital tools like the "Drug Procurement Browser," which aggregates data from multiple B2B platforms to find the best prices [5][6] - This tool allows pharmacy owners to have a "God's perspective," enabling them to negotiate better prices and make informed purchasing decisions [7] - Implementing data-driven decision-making can significantly improve inventory turnover rates, with reported increases of over 30% [9] Group 3: Future of the Pharmacy Industry - The industry is anticipating a major shift by 2026, with stricter regulations and market consolidation, making digitalization essential for survival [10] - Efficiency will become a key competitive factor, and traditional methods like phone calls and Excel spreadsheets will not suffice [10] - Pharmacy owners are encouraged to adopt digital tools as price comparison aids to avoid overpaying due to information asymmetry [11][12]